Concizumab

Drug Profile

Concizumab

Alternative Names: Anti-TFPI monoclonal antibody; mAb-2021; NN-7415; NNC-0172-0000-2021; NNC-0172-2021; NNC-172-2021

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 16 Aug 2017 Phase-II clinical trials in Haemophilia (Prevention) in Japan, Germany (SC) (NCT03196297)
  • 16 Aug 2017 Novo Nordisk initiates enrolment in a phase II trial in Haemophilia (Prevention) in Spain, Sweden (SC) (NCT03196297)
  • 10 Aug 2017 Phase-II clinical trials in Haemophilia (Prevention) in Spain, Austria, Denmark (SC) (NCT03196284) (EudraCT2016-000510-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top